ANDA 202058, held by HEC Pharm. Zidovudine.
As of Nov 18, 2026, ANDA 202058 (Zidovudine), held by HEC Pharm, was first approved by FDA on Oct 7, 2011, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 7, 2011 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Zidovudine300MG · tablet;oral | Zidovudine | Discontinued |
| Jan 22, 2020 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 22, 2020 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jun 3, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 1, 2013 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 7, 2011 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters